
April 14 (Reuters) - Valneva SE VLS.PA:
VALNEVA SAYS BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA) HAS GRANTED MARKETING AUTHORIZATION TO ITS SINGLE-DOSE VACCINE IXCHIQ
VALNEVA RECEIVES FIRST MARKETING AUTHORIZATION FOR IXCHIQ® IN A CHIKUNGUNYA ENDEMIC COUNTRY
APPROVAL ENABLES INITIATION OF LARGE-SCALE CLINICAL TRIALS OF IXCHIQ® IN BRAZIL, INCLUDING COMMITTED PHASE 4 CLINICAL TRIALS